MetaVia

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MetaVia and other ETFs, options, and stocks.

About MTVA

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. 

CEO
Hyung-Heon Kim
CEOHyung-Heon Kim
Employees
8
Employees8
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2014
Founded2014
Employees
8
Employees8

MTVA Key Statistics

Market cap
7.66M
Market cap7.66M
Price-Earnings ratio
-0.16
Price-Earnings ratio-0.16
Dividend yield
Dividend yield
Average volume
139.78K
Average volume139.78K
High today
$1.56
High today$1.56
Low today
$1.40
Low today$1.40
Open price
$1.54
Open price$1.54
Volume
112.55K
Volume112.55K
52 Week high
$23.10
52 Week high$23.10
52 Week low
$1.17
52 Week low$1.17

Stock Snapshot

MetaVia(MTVA) stock is priced at $1.43, giving the company a market capitalization of 7.66M. It carries a P/E multiple of -0.16.

On 2026-04-15, MetaVia(MTVA) stock moved within a range of $1.40 to $1.56. With shares now at $1.43, the stock is trading +2.2% above its intraday low and -8.5% below the session's peak.

Trading activity shows a volume of 112.55K, compared to an average daily volume of 139.78K.

The stock's 52-week range extends from a low of $1.17 to a high of $23.10.

The stock's 52-week range extends from a low of $1.17 to a high of $23.10.

MTVA News

TipRanks 5d
MetaVia Advances DA-1726 Obesity Trial With First Patient

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 5d
MetaVia says first patient dosed in Part 3 of Phase 1 trial of DA-1726

MetaVia (MTVA) announced that the first patient has been dosed in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog tar...

People also own

Based on the portfolios of people who own MTVA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.